[
    [
        {
            "time": "",
            "original_text": "推荐评级 泰格医药(300347)：长期受益于国内创新药产业发展 临床CRO龙头优势突出",
            "features": {
                "keywords": [
                    "泰格医药",
                    "创新药",
                    "产业发展",
                    "临床CRO",
                    "龙头优势"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "推荐评级 泰格医药(300347)：长期受益于国内创新药产业发展 临床CRO龙头优势突出",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]